Surviving Myeloma Profile
Surviving Myeloma

@grpetersen1

Followers
4K
Following
7K
Media
569
Statuses
18K

editor of http://t.co/sregDYpJyN

Jacksonville, Fl
Joined March 2012
Don't wanna be here? Send us removal request.
@grpetersen1
Surviving Myeloma
2 days
Remains the most important template for patients and hematologist/oncologists as a critical reference.
@VincentRK
Vincent Rajkumar
2 days
Updated mSMART guidelines on treatment of newly diagnosed myeloma. Major change: For standard risk myeloma, doublet maintenance (lenalidomide plus anti CD38) recommended if MRD+ post transplant. https://t.co/R4hz7ulYPb
2
6
36
@VincentRK
Vincent Rajkumar
13 days
I am scared of using CART or bispecifics in myeloma with large volume disease: CRS, neurotoxicity, HLH, risk of death, and all kinds of complications are much higher. I’d rather control myeloma and get it to low volume before using these immunotherapy treatments. This is why
16
44
232
@VincentRK
Vincent Rajkumar
13 days
How I manage MGUS in one Figure 👇
@NEJM
NEJM
17 days
Management of Monoclonal Gammopathy of Undetermined Significance. In low-risk patients who are younger than 50 years of age, bone marrow biopsy and imaging may be considered a baseline evaluation, given the anticipated life expectancy. Learn more: https://t.co/OiMcemqVJg
6
79
254
@IMFsupport
Robin Tuohy
22 days
If your insurance company says no: APPEAL! It works 40-60% of the time! ⁦@IMFmyeloma#mmsm #myeloma@jmikhaelmd⁩ ⁦@JWiework⁩ ⁦@TriageCancer
0
5
11
@grpetersen1
Surviving Myeloma
28 days
So true, but so misunderstood!
@HealthTree
HealthTree Foundation
28 days
Every single #myeloma patient needs to know their genetic features. So many new myeloma therapies that can be customized to your needs. Dr. Ajay Nooka shares options for relapsed patients at the HealthTree Myeloma Atlanta Roundtable. #mmsm
0
0
1
@mtmdphd
Mike Thompson, MD, PhD, FASCO
3 years
Myeloma / Plasma Cell Dyscrasia ~ #ASH22Top10 (or so) #mmsm #mmMRD #ASH22 - @mtmdphd *DRAFT* Table Update: Dec 10, 2022 v2 cc @grpetersen1 & @Mohty_EBMT @VincentRK + @MyelomaTeacher @IreneGhobrial
1
8
12
@grpetersen1
Surviving Myeloma
1 month
The innovators often see the future when the mainstream are blind to the possibility! Dr. Kyle and Dr. Barlogie were visionaries!
@VincentRK
Vincent Rajkumar
1 month
Philippe Moreau at #IMS25 opening lecture: Bob Kyle as early as 1985 proposed possibility of monoclonal antibodies for treatment of myeloma. Incredible. I did not know.
0
0
1
@VincentRK
Vincent Rajkumar
1 month
What cure looks like. #IMS25 This is what we should aspire for and define as cure in myeloma and other cancers. 1/
2
13
101
@IMFsupport
Robin Tuohy
1 month
Do you #knowmyeloma ? We do! Living with #myeloma for 25 years and grateful for each day together! ⁦@IMFmyeloma⁩ ⁦@IMFmikeMYELOMA
0
5
23
@IMFjimMYELOMA
Jim Omel
2 months
After 5 Years of No CR MRD with Cilta-Cel, No Maintenance Required https://t.co/QYf0IThKf8 via @@CancerNetwrk Dr.Jagannath reports that 12 out of 37 multi-treated patients, free of disease after 5 years, should be called "cured".
Tweet card summary image
cancernetwork.com
Results from the phase 1b/2 CARTITUDE-1 trial showed that after patients receiving cilta-cel were disease-free for 5 years, they did not need maintenance therapy.
0
1
4
@NorthTxMSG
Yelak Biru
3 months
SWIFT-seq is a powerful option as it can measure the number of CTCs, characterize the genomic alterations of the tumor, estimate the tumor’s proliferative capacity and measure prognostically useful gene signatures in a single test and from a blood sample,” said Dr.
6
14
54
@grpetersen1
Surviving Myeloma
3 months
Outstanding to have an alternative to the often painful Bone Marrow Biopsy!
@NorthTxMSG
Yelak Biru
3 months
SWIFT-seq is a powerful option as it can measure the number of CTCs, characterize the genomic alterations of the tumor, estimate the tumor’s proliferative capacity and measure prognostically useful gene signatures in a single test and from a blood sample,” said Dr.
4
8
28
@grpetersen1
Surviving Myeloma
3 months
Just amazing! The US was nearly always the first to recognize new drug efficacy, not the first to kill a really great new treatment.
@chadinabhan
chadi nabhan MD, MBA, FACP
3 months
Recently, ODAC voted "NO" on approving Blenrep 4 R/R Myeloma. In a back-to-back #HUExpress, I get @VincentRK thoughts on that decision and I also host @GregNowakowski to give us "behind the scenes" on what happened that day at ODAC. Two must watch EPs coming your way this week.
0
0
1
@VincentRK
Vincent Rajkumar
4 months
.@Costplusdrugs could have had a business model that increased profits and still deliver low cost prescription drugs. But they chose not to chase profits but go with a bare bones fixed flat 15% markup model. No wonder prices are dramatically lower. This reflects the genuine
19
36
188
@NoopurRajeMD
Noopur Raje
4 months
This is our first @Myeloma_Society educational session in Northern Africa in collaboration with SMH.. 🙏 to our moroccan colleagues.. global education for #mmsm!
@melmehdi
M. El Mehdi م. المهدي
4 months
. @NoopurRajeMD talk about imaging techniques in myeloma #mmsm @Myel_Society
3
12
54
@NikhilMunshiMD
Nikhil C. Munshi, MD
4 months
Major Regulatory Milestone in MM: In response to an application by I2TEAMM and @IMFmyeloma, the European Medicines Agency has officially endorsed MRD as an early endpoint in clinical trials for Myeloma. This marks a transformative step forward in drug development !! @VincentRK
6
37
107
@grpetersen1
Surviving Myeloma
4 months
Dr. Rajkumar has been a champion for lower drug costs and without his effort and leadership along with other advocates for change, nothing would have changed!
@VincentRK
Vincent Rajkumar
1 year
Why are prescription drug prices are far higher in the US that other developed countries. I’ll break it down. A full 360. 1/ We don’t negotiate prices at launch of a new drug. Others do.
1
1
11
@VincentRK
Vincent Rajkumar
1 year
Why are prescription drug prices are far higher in the US that other developed countries. I’ll break it down. A full 360. 1/ We don’t negotiate prices at launch of a new drug. Others do.
13
117
301
@VincentRK
Vincent Rajkumar
4 months
Breaking: Big news for smoldering myeloma. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of a new indication for DARZALEX®(daratumumab) subcutaneous (SC) formulation as monotherapy for the treatment
8
48
205